Kyntra Bio (KYNB) AI Stock Analysis

• Market Cap: $31.88M
• Dividend Yield: N/A
• Average Volume (3M): 30.76K
• Price to Earnings (P/E): 0.2
• Beta (1Y): 1.37
• Revenue Growth: -95.39%
• EPS Growth: N/A
• Country: US
• Employees: 225
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 49.61
• Shares Outstanding: 4,045,445
• 10 Day Avg. Volume: 33,010
• 30 Day Avg. Volume: 30,760
• PEG Ratio: 0.33
• Price to Book (P/B): -5.87
• Price to Sales (P/S): 44.72
• P/FCF Ratio: -9.58
• Enterprise Value/Market Cap: -2.09
• Enterprise Value/Revenue: 0.56
• Enterprise Value/Gross Profit: 0.68
• Enterprise Value/Ebitda: 0.52
• 1Y Price Target: $43.00
• Price Target Upside: 445.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $8.00 ▲(1.52% Upside)

The score is held back primarily by weak financial performance (declining revenue, negative cash flows, and negative equity). Offsetting positives come from earnings-call updates—cash runway extended into 2028 via the China sale and sharply reduced operating costs—while technicals are mixed and valuation looks optically low but is hard to underwrite given current fundamentals.

Positive Factors

Extended cash runway from asset sale

The ~$220M divestiture materially improves near-to-medium term liquidity, reducing immediate refinancing pressure and enabling continued financing of core R&D and ongoing trials. This structural cash buffer supports execution flexibility and lowers short-term dilution risk for 2–6+ months.

Material operating cost reduction

An 86% YoY cut in operating expenses signals a durable structural shrinkage of cash burn, improving margin sustainability and extending runway even absent revenue growth. Lower fixed overhead increases optionality to fund prioritized trials and preserves capital for value-driving milestones.

Regulatory and clinical pathway progress

Constructive FDA engagement and a planned Phase III protocol submission represent a structural reduction in regulatory uncertainty for roxadustat. Clearer pathways enhance the long-term probability of approval and commercialization, supporting strategic value capture beyond short-term market moves.

Negative Factors

Weak historical financial performance

Sustained revenue declines, negative margins and negative equity are structural concerns that undermine solvency and restrict strategic options. These issues increase reliance on asset sales or external financing, raising dilution and execution risk across clinical programs over the coming months.

Persistent negative operating and free cash flow

A continuing cash burn trajectory limits the company's internal ability to fund trials and commercialization, forcing dependence on one-time asset transactions or external capital. This structural cashflow weakness constrains reinvestment capacity and heightens financing risk into 2–6 months.

Phase III trial cost pressure

A $50–$60M Phase III bill is a material structural expenditure that can meaningfully deplete existing cash reserves and necessitate partnering or new capital. Even with recent asset-sale proceeds, funding large late-stage trials presents sustained execution and financing risk over the medium term.

Kyntra Bio Business Overview & Revenue Model

Company Description

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

How the Company Makes Money

FibroGen generates revenue through several key streams. The primary source of income comes from the sale of its approved products, such as roxadustat, in markets where it is commercially available. Additionally, the company may receive milestone payments and royalties from partnerships and collaborations with other pharmaceutical companies that help develop and market its products. Significant partnerships, such as those with larger biopharmaceutical firms, can also provide upfront payments and shared funding for research and development activities. Furthermore, grants and funding from government and non-profit organizations can supplement its revenue, particularly for the advancement of its pipeline projects.

Kyntra Bio Financial Statement Overview

Summary

Financial statements indicate material strain: declining revenues over multiple years, historically negative margins, persistently negative operating/free cash flow, and negative stockholders’ equity creating solvency risk despite some debt reduction.

Income Statement

FibroGen's income statement reveals significant challenges. The company has experienced negative revenue growth over the past few years, with a sharp decline in total revenue from 2020 to 2025. Despite a positive net income in the TTM period, historical net profit margins have been negative, indicating profitability issues. The EBIT and EBITDA margins have also been consistently negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity in recent years, indicating potential solvency issues. The debt-to-equity ratio is negative due to negative equity, which poses a risk. Although the company has managed to reduce total debt, the negative equity ratio and low return on equity highlight financial instability.

Cash Flow

Cash flow analysis indicates persistent negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting cash flow challenges. However, the free cash flow to net income ratio is slightly above 1, indicating some ability to cover net income with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-118.09M	29.62M	46.80M	140.73M	235.31M	176.32M
Gross Profit	-97.71M	14.06M	42.84M	120.45M	-213.88M	167.45M
EBITDA	-127.70M	-142.43M	-305.20M	-282.82M	-333.72M	-164.28M
Net Income	215.65M	-47.58M	-284.23M	-293.65M	-290.02M	-189.29M
Balance Sheet
Total Assets	137.01M	214.53M	423.53M	610.09M	773.82M	826.84M
Cash, Cash Equivalents and Short-Term Investments	117.97M	50.48M	235.59M	422.01M	405.19M	686.54M
Total Debt	19.47M	90.17M	170.46M	89.89M	99.72M	39.76M
Total Liabilities	119.53M	398.16M	585.73M	611.57M	544.71M	385.39M
Stockholders Equity	-17.03M	-225.60M	-204.17M	-21.45M	209.15M	422.18M
Cash Flow
Free Cash Flow	-17.09M	-138.26M	-317.54M	-184.67M	-112.42M	77.61M
Operating Cash Flow	-16.91M	-138.00M	-315.02M	-145.93M	-82.23M	81.60M
Investing Cash Flow	88.85M	125.99M	153.66M	89.12M	-426.97M	452.49M
Financing Cash Flow	-86.01M	-255.00K	122.75M	46.78M	-563.00K	13.34M

Kyntra Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYNB, the sentiment is Negative. The current price of 7.88 is below the 20-day moving average (MA) of 8.90, below the 50-day MA of 8.73, and below the 200-day MA of 8.93, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 37.88 is Neutral, neither overbought nor oversold. The STOCH value of 21.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYNB.

Kyntra Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$56.17M	-6.21	-13.15%	―	―	45.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KYNB	51 Neutral	$31.88M	0.19	―	―	-95.39%	―
XLO	49 Neutral	$40.18M	-0.90	-908.28%	―	588.40%	61.76%
SNTI	48 Neutral	$26.29M	-0.30	-394.62%	―	―	78.60%
OKUR	42 Neutral	$35.77M	-0.43	-115.64%	―	―	46.20%
GBIO	39 Underperform	$37.66M	-0.60	-80.81%	―	-17.82%	57.32%